Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jan 24, 2021; 12(1): 6-12
Published online Jan 24, 2021. doi: 10.5306/wjco.v12.i1.6
Published online Jan 24, 2021. doi: 10.5306/wjco.v12.i1.6
Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
Ivan Henriquez, Department of Radiation Oncology, Hospital Universitario Sant Joan, Instituto Investigación Pere i Virgili, Reus 43204, Tarragona, Spain
Daniel Spratt, Department of Radiation Oncology, Ann Arbor, University of Michigan, Michigan, MI 48109, United States
Alfonso Gómez-Iturriaga, Department of Radiation Oncology, Hospital Universitario Cruces/Biocruces Health Research Institute, Barakaldo 48903, Bizcaia, Spain
Oscar Abuchaibe, Department of Radiation Oncology, Virgilio Galvis Ramirez Cancer Centre, Bucaramanga s/n, Santander, Colombia
Felipe Couñago, Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Pozuelo de Alarcón, Hospital La Luz, Clinical Department, Faculty of Biomedicine, Universidad Europea, Madrid 28223, Spain
Author contributions: Henriquez I, Spratt D, Gómez-Iturriaga A, Abuchaibe O, and Couñago F contributed equally to this work.
Conflict-of-interest statement: The authors have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ivan Henriquez, MD, PhD, Academic Research, Doctor, Medical Assistant, Department of Radiation Oncology, Hospital Universitario Sant Joan, Instituto Investigación Pere i Virgili, Av. Josep Laporte 2, Reus 43204, Tarragona, Spain.
Received: September 10, 2020
Peer-review started: September 10, 2020
First decision: November 16, 2020
Revised: December 1, 2020
Accepted: December 13, 2020
Article in press: December 13, 2020
Published online: January 24, 2021
Processing time: 128 Days and 23.5 Hours
Peer-review started: September 10, 2020
First decision: November 16, 2020
Revised: December 1, 2020
Accepted: December 13, 2020
Article in press: December 13, 2020
Published online: January 24, 2021
Processing time: 128 Days and 23.5 Hours
Core Tip
Core Tip: The main focus of this editorial is to review novel treatments for nonmetastatic castration-resistant prostate cancer (nmCRPC). The three-practice changing pivotal randomized controlled trials - PROSPER, SPARTAN, and ARAMIS - are reviewed. We discuss the findings of these trials, emphasizing the strengths of the studies and critically examining controversies related to the diagnosis of nmCRPC and the role of advanced imaging techniques and molecular determinants.